Logo image of EVGN

EVOGENE LTD (EVGN) Stock Fundamental Analysis

NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD

1.16  -0.04 (-3.33%)

After market: 1.17 +0.01 (+0.86%)

Fundamental Rating

2

Overall EVGN gets a fundamental rating of 2 out of 10. We evaluated EVGN against 553 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EVGN had negative earnings in the past year.
In the past year EVGN has reported a negative cash flow from operations.
In the past 5 years EVGN always reported negative net income.
In the past 5 years EVGN always reported negative operating cash flow.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EVGN's Return On Assets of -44.34% is in line compared to the rest of the industry. EVGN outperforms 53.53% of its industry peers.
Industry RankSector Rank
ROA -44.34%
ROE N/A
ROIC N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

EVGN's Gross Margin of 41.06% is fine compared to the rest of the industry. EVGN outperforms 75.05% of its industry peers.
In the last couple of years the Gross Margin of EVGN has declined.
EVGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVGN has more shares outstanding
The number of shares outstanding for EVGN has been reduced compared to 5 years ago.
EVGN has a worse debt/assets ratio than last year.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -13.06, we must say that EVGN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EVGN (-13.06) is worse than 78.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.06
ROIC/WACCN/A
WACC5.83%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.06 indicates that EVGN should not have too much problems paying its short term obligations.
EVGN has a worse Current ratio (1.06) than 86.62% of its industry peers.
A Quick Ratio of 0.92 indicates that EVGN may have some problems paying its short term obligations.
EVGN has a Quick ratio of 0.92. This is amonst the worse of the industry: EVGN underperforms 88.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.92
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.52% over the past year.
Looking at the last year, EVGN shows a very negative growth in Revenue. The Revenue has decreased by -26.35% in the last year.
The Revenue has been growing by 62.55% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.5%
Revenue 1Y (TTM)-26.35%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-41.77%

3.2 Future

EVGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.69% yearly.
EVGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.55% yearly.
EPS Next Y27.52%
EPS Next 2Y22.2%
EPS Next 3Y18.69%
EPS Next 5YN/A
Revenue Next Year-38.61%
Revenue Next 2Y14.4%
Revenue Next 3Y23.55%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as EVGN's earnings are expected to grow with 18.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.2%
EPS Next 3Y18.69%

More info and screens

0

5. Dividend

5.1 Amount

EVGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOGENE LTD

NASDAQ:EVGN (8/1/2025, 8:00:02 PM)

After market: 1.17 +0.01 (+0.86%)

1.16

-0.04 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-21 2025-05-21/bmo
Earnings (Next)08-19 2025-08-19/bmo
Inst Owners6.53%
Inst Owner Change0%
Ins Owners1.26%
Ins Owner ChangeN/A
Market Cap10.10M
Analysts82.5
Price Target3.57 (207.76%)
Short Float %1.76%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.12%
Min EPS beat(2)18.12%
Max EPS beat(2)108.11%
EPS beat(4)3
Avg EPS beat(4)28.98%
Min EPS beat(4)-27.16%
Max EPS beat(4)108.11%
EPS beat(8)7
Avg EPS beat(8)24.63%
EPS beat(12)10
Avg EPS beat(12)23.17%
EPS beat(16)12
Avg EPS beat(16)18.04%
Revenue beat(2)0
Avg Revenue beat(2)-39.85%
Min Revenue beat(2)-56.44%
Max Revenue beat(2)-23.27%
Revenue beat(4)1
Avg Revenue beat(4)-26.48%
Min Revenue beat(4)-56.44%
Max Revenue beat(4)12.01%
Revenue beat(8)4
Avg Revenue beat(8)13.76%
Revenue beat(12)7
Avg Revenue beat(12)58.27%
Revenue beat(16)8
Avg Revenue beat(16)39.37%
PT rev (1m)0%
PT rev (3m)-36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-52.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-54.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.78
BVpS-0.42
TBVpS-1.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.06%
FCFM N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.25%
Cap/Sales 8.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.92
Altman-Z -13.06
F-Score3
WACC5.83%
ROIC/WACCN/A
Cap/Depr(3y)33.47%
Cap/Depr(5y)32.69%
Cap/Sales(3y)30.31%
Cap/Sales(5y)49.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.5%
EPS Next Y27.52%
EPS Next 2Y22.2%
EPS Next 3Y18.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-26.35%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-41.77%
Revenue Next Year-38.61%
Revenue Next 2Y14.4%
Revenue Next 3Y23.55%
Revenue Next 5YN/A
EBIT growth 1Y3.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.97%
EBIT Next 3Y23.41%
EBIT Next 5YN/A
FCF growth 1Y8.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.47%
OCF growth 3YN/A
OCF growth 5YN/A